Prognostic Effects of Combined Treatment With Calcium Channel Blockers and Statins in Patients With Coronary Narrowing From the Japanese Coronary Artery Disease Study
| Autor: | Tsutomu Yamazaki, Dobun Hayashi, Masatoshi Fujita, Ryozo Nagai, Shigetake Sasayama, Yoshihiro Okada, Satoko Mitani, Takahide Kohro |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Cholesterol business.industry General Medicine medicine.disease Coronary artery disease Coronary arteries chemistry.chemical_compound Blood pressure Pharmacotherapy medicine.anatomical_structure chemistry Internal medicine Propensity score matching Cardiology medicine Clinical endpoint Population study Cardiology and Cardiovascular Medicine business |
| Zdroj: | International Heart Journal. 51:299-302 |
| ISSN: | 1349-3299 1349-2365 |
| DOI: | 10.1536/ihj.51.299 |
| Popis: | Calcium channel blockers (CCB) and statins are frequently prescribed for patients with coronary artery disease (CAD) complicated by hypertension and/or hypercholesterolemia. CCB have pleiotropic actions beyond their blood pressure-lowering effect, while statins have pleiotropic actions beyond their cholesterol-lowering effect. We assessed the hypothesis that combined treatment with CCB and statins has additional prognostic benefits resulting from potential additive or synergistic pleiotropic actions of both classes of drugs in the Japanese CAD (JCAD) study population. The JCAD study consisted of 13,812 patients with angiographically demonstrable significant coronary narrowing in at least 1 of 3 major coronary arteries who were followed-up for a mean of 2.7 years (follow-up rate, 88.4%). The primary endpoint of the present study was all cardiovascular events. We compared the event rate between patients receiving neither CCB nor statins and those receiving each drug alone or as a combination treatment using propensity score matching analysis. The rate of all events was 62.8 per 1,000 patient-years in the JCAD study. Kaplan-Meier analysis with the log-rank test showed no statistically significant difference in the event rate in each comparison. In conclusion, there may be no additional prognostic benefit beyond the blood-pressure-lowering and cholesterol-lowering effects in the combined treatment with CCB and statins for angiographically documented CAD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|